The process of drug discovery is intricate, and encompasses a series of detailed phases of research, development, and testing, aimed at evaluating the safety and effectiveness of prospective therapeutic agents. Artificial Intelligence has emerged as a transformative tool in this domain, adept at analysing vast datasets to uncover intricate patterns and relationships unperceivable to humans. This study introduces a bioactivity prediction application employing the Quantitative Structure-Activity Relationship model to forecast bioactivity against Angiotensin II receptor, a major drug target in hypertension management. Angiotensin II receptor modulation holds promise for treating a spectrum of diseases, including hypertension, cardiovascular ailments, and renal disorders. Through AI-driven approaches researchers in the field of drug discovery are able to effectively identify a majority of promising drug candidates, expediting the lead optimization process while reducing costs. This paradigm shift not only accelerates therapeutic development but also minimizes the need for exhaustive in vitro or in vivo testing, thus enhancing the efficiency of drug discovery endeavours.